Literature DB >> 380618

Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.

R I Nicholson, P V Maynard.   

Abstract

Experiments were undertaken with DMBA-induced mammary tumours of the rat to determine the anti-tumour properties of a new and potent luteinizing hormone releasing hormone (LH-RH) agonist, [D-Ser(But) 6Azgly10]-LH-RH (ICI 118630). Tumours were classified according to their oestrogen-receptor (ER) content. Twice daily i.m. injections of either 5 micrograms or 0.5 micrograms ICI 118630 in saline were as effective as ovariectomy or tamoxifen therapy in causing the regression of ER+ DMBA-induced mammary tumours. ER- mammary tumours showed a more equivocal overall response to ICI 118630, some tumours progressing, others regressing. About one-third of the ER+ tumours disappeared in the 20-day treatment period. Those tumours which did regrow after the cessation of treatment proved to be hormone-dependent. In addition to the inhibitory effects of the LH-RH agonist on pre-existing tumours, ICI 118630 also reduced the total number of new tumours formed during and after treatment.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 380618      PMCID： PMC2009890          DOI： 10.1038/bjc.1979.50

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  9 in total

1.  Potent agonist and antagonist analogues of luliberin containing an azaglycine residue in position 10.

Authors:  A S Dutta; B J Furr; M B Giles; B Valcaccia; A L Walpole
Journal:  Biochem Biophys Res Commun       Date:  1978-03-30       Impact factor: 3.575

2.  The nature of estrogen and prolactin effect on mammary tumorigenesis.

Authors:  D Sinha; D Cooper; T L Dao
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

3.  A dissociation between ovarian dependent growth and estrogen sensitivity in mammary carcinoma.

Authors:  W L McGuire; J A Julian; G C Chamness
Journal:  Endocrinology       Date:  1971-10       Impact factor: 4.736

4.  The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours.

Authors:  R I Nicholson; M P Golder
Journal:  Eur J Cancer       Date:  1975-08       Impact factor: 9.162

5.  Synthesis and biological activity of highly active alpha-aza analogues of luliberin.

Authors:  A S Dutta; B J Furr; M B Giles; B Valcaccia
Journal:  J Med Chem       Date:  1978-10       Impact factor: 7.446

6.  Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7, 12- dimethylbenz (a)anthracene-induced rat mammary tumors. Histological and endocrine studies.

Authors:  A Danguy; N Legros; J A Heuson-Stiennon; J L Pasteels; G Atassi; J C Heuson
Journal:  Eur J Cancer       Date:  1977-10       Impact factor: 9.162

7.  Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors.

Authors:  C HUGGINS; G BRIZIARELLI; H SUTTON
Journal:  J Exp Med       Date:  1959-01-01       Impact factor: 14.307

8.  THE RESPONSE OF EXPERIMENTALLY INDUCED MAMMARY TUMOURS IN RATS TO HYPOPHYSECTOMY AND TO PITUITARY STALK SECTION.

Authors:  P M DANIEL; M M PRICHARD
Journal:  Br J Cancer       Date:  1963-09       Impact factor: 7.640

9.  Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats.

Authors:  P V Maynard; R I Nicholson
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640
  9 in total
  16 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.

Authors:  Susan M Cheer; Greg L Plosker; Dene Simpson; Antona J Wagstaff
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

4.  Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments.

Authors:  J G Klijn
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

5.  Increased survival due to radioactive estradiol in mice with C3HBA or BW 10232 tumors.

Authors:  B Thysen; G Rettura; J Padawer; M Gatz; S M Levenson; E Seifter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.

Authors:  J G Klijn; F H de Jong; M A Blankenstein; R Docter; J Alexieva-Figusch; J Blonk-van der Wijst; S W Lamberts
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

7.  Unresponsiveness of the reproductive organs of the male mouse to treatment with a potent luteinizing hormone-releasing hormone agonist (ICI-118,630).

Authors:  G J van Steenbrugge; J C Romijn; F H de Jong; F H Schröder
Journal:  Urol Res       Date:  1984

8.  Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.

Authors:  A V Schally; T W Redding; A M Comaru-Schally
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

9.  Inhibition of growth of the transplantable rat chondrosarcoma by analogs of hypothalamic hormones.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

10.  Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.

Authors:  T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.